594 results about "Streptococcus bacteria" patented technology

The present invention provides methods for tagging and / or identifying microorganisms. In some preferred embodiments, the microorganisms are bacteria. In some particularly preferred embodiments, the bacteria are members of the genus Streptococcus, while in other embodiments, the bacteria are members of other genera. The present invention also provides microorganisms tagged using the methods set forth herein. In some preferred embodiments, the tagged microorganisms are bacteria. In some particularly preferred embodiments, the tagged bacteria are members of the genus Streptococcus, while in other embodiments, the tagged bacteria are members of other genera.

The present invention relates to novel vaccines for the prevention or attenuation of infection by Streptococcus pneumoniae. The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of Streptococcus pneumoniae. Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention additionally relates to diagnostic methods for detecting Streptococcus nucleic acids, polypeptides and antibodies in a biological sample.

The invention relates to the use of a composition comprising n Streptococcus pneumoniae polysaccharides conjugated to the tetanus toxoid and p Streptococcus pneumoniae polysaccharides conjugated to the diphtheria toxoid, for manufacturing a vaccine which protects against Clostridium tetani and / or Corynebacterium diphtheriae infections in which: (1) n and p are other than 1, with p being, however, <=15, (2) 2<=n+p<=38, (3) the total amount of conjugated toxoid present in one vaccine dose is sufficient to induce protection against Clostridium tetani and / or Corynebacterium diphtheriae infections.

The invention belongs to the field of genetic engineering, and discloses a target sequence, recognized by a streptococcus thermophilus CRISPR-Cas9 system, of a human CCR5 gene, sgRNA and an application of the CRISPR-Cas9 system. The target sequence is shown as any one of the nth bit to the 30th bit of the SEQ ID NO:1-30, and n is equal to 1-12. The invention further relates to the sgRNA of the sequence -3' with the sequence of 5'-recognition sequence-recruiting Cas9 protein and a coded DNA molecule thereof. The DNA sequence corresponding to the recognition sequence is identical to the target sequence. The invention further relates to the CRISPR-Cas9 system. The system comprises Cas9 protein, the sgRNA and / or the coded sequence carrying the Cas9 protein and a carrier of the coded sequence of the sgRNA. The invention further relates to the application of the CRISPR-Cas9 system in editing the CCR5 gene and preparing medicine for HIV infection. Editing of the human CCR5 gene can be achieved, and therefore Aids is prevented and treated.

The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence is selected from the group comprising SEQ ID NO 11 to SEQ ID NO 20, and the use of such polypeptide for the manufacture of a vaccine.

Methods and compositions comprising isolated nucleic acid molecules specific to Streptococcus pneumoniae and Streptococcus pyogenes, as well as vector constructs and isolated polypeptides specific to Streptococcus pneumoniae and Streptococcus pyogenes are provided. Such compositions and methods are useful for the diagnosis of Streptococcal infection and for generating an immune response to Streptococcal bacteria.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

The invention discloses a streptococcus-A quantum dot immunochromatographic detection reagent card and a preparation method of the streptococcus-A quantum dot immunochromatographic detection reagent card, and aims to provide the streptococcus-A quantum dot immunochromatographic detection reagent card which is simple, high in sensitivity and reliable in detection results. The detection reagent card comprises a box body (6), wherein a piece of detection test paper is arranged in the box body (6); the detection test paper comprises a bottom plate (1); a sample pad (2), an anti-streptococcus-A quantum dot anti-body markup pad (3), a coating film (4) and a water absorption pad (5) are connected with the bottom plate (1) in sequence; a streptococcus-A quantum antibody detection area line T and a goat anti-rabbit polyclonal anti-body quality control area line C are arranged on the coating film (4); the two lines are arranged in parallel; the streptococcus-A quantum dot immunochromatographic detection reagent card and the preparation method thereof belong to the field of fluorescence immunoassay.

The invention concerns a new lipoteichoic acid which can be isolated from the new Streptococcus sp DSM 8747. The new LTA is called LTA-T. It has a lipid anchor, which is a galacto-furanosyl-beta-1-3-glycerol with different rests of fatty acids esterified in the two adjacent hydroxy groups in the glycerol moiety and a non-glycosylated, linear, unbranched GroP chain with an unusual short hydrophilic GroP chain. The hydrophilic backbone consists of only 10 glycerophosphate units esterified with D-alanine in an extent of 30%. The invention further concerns a pharmaceutical composition with the new LTA-T, optionally together with a monokine and / or hyaluronidase, a method of treating cancer comprising administration of an antitumor effective amount thereof, a method of producing the new compound and the new pharmaceutical composition, two degradation products of the new LTA-T and their use, and the new Streptococcus strain from which the new compound can be isolated.

The invention discloses a novel method for producing high molecular weight sodium hyaluronate (HA-Na) with amino acid complex liquid as a nitrogen source through fermentation. In the method for producing the high molecular weight sodium hyaluronate, provided by the invention, yeast cream or yeast powder is replaced with the amino acid complex liquid as a fermentation nitrogen source of streptococcus zooepidemicus. The HA-Na with molecular weight of 2.2*10<6>D is obtained through control of a fermentation process. When the method is applied to industrial production, on the one hand, contents of hetero-protein and pigment in fermentation liquid can be effectively reduced, the step of subsequent HA-Na extraction is decreased, and the physical damage of the molecular weight of HA-Na in the fermentation liquid in the extraction process is reduced; on the other hand, the HA-Na production cost can be lowered, and the novel method has higher industrial application value. The HA-Na produced by the method has the molecular weight of 2.0-2.2*10<6>D, the alduronic acid content of 42.4-43.5%, the intrinsic viscosity of 3,064-3,115 and the protein content of 0.1%.

The present invention provides an optimal formulation of multiple serotype Streptococcus pneumoniae conjugate vaccines.

The invention proposes a nutritional composition comprising selected oligosaccharides that reduces the abundance of Streptococcus bacteria in the gut of infants or young mammals. The infants are preferably infants in needs presenting a relatively high count of Streptococcus. Ultimately the reduction of streptococcus and the related microbiota balance affects and lowers the risk of adiposity or obesity later in life.

The invention relates to an oral probiotic composition, which contains Streptococcus salivarius K12, and one or more of the Chinese herb extract effective ingredients eugenol, tea polyphenol, glycyrrhizic acid, menthol, radix scrophulariae total glycoside, hericium erinaceus polysaccharide, Pachymaran, a dark plum water extract, and pueraria isoflavone. The composition can adjust oral flora balance, clean the oral cavity and improve oral air, and also has the efficacy of diminishing inflammation and relieving sore swollen throat.

A method of suppressing bacteria that cause infections of the throat, sinuses, heart and arteries, and joints (arthritis) by delivering xylitol in a human mouth. The method is effective with troches of pure xylitol or with xylitol chewing gum or liquid, provided sufficient quantities of xylitol are delivered. Streptococcus mutans and Staphylococcus aureus in the blood are important contributors to plaque in arteries and on heart valves and bacterial arthritis. For people whose blood is not already infected with significant levels of these bacteria, every day use of xylitol sufficient to suppress these bacteria in the oral cavity will reduce their risk of subsequent cardiovascular disease, arthritis, and sinus infections. Strep throat is a common throat infection caused by Streptococcus pyogenes. Frequent bathing with xylitol, such as from time release in the mouth, will speed recovery from strep throat.

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Methods for identifying strains of bacteria, particularly methods for serotyping Streptococcus pneumoniae in a sample, methods for detecting and / or classifying S. pneumoniae infection by serotype, array devices and kits for use in such methods are disclosed. Array devices comprise a set of capture antibodies immobilised on a substrate at pre-determined array positions, wherein the set of capture antibodies comprises serotype-distinguishing antibodies which differ in their binding specificity for different S. pneumoniae serotypes. Serotyping methods may employ whole cell detection utilising one or more detectable labels, including in situ labelling of array-bound cells.

Disclosed is a skin property-improving agent which exerts excellent effects by oral administration. The skin property-improving agent for oral administration contains, as an active ingredient, a bacterium belonging to the genus Streptococcus and a bacterium belonging to the genus Bifidobacterium, or fermented milk containing the two bacteria.

The invention provides a truncated-form streptococcus hemolyticus bacteriolysin O gene and an ASO detection kit. According to the invention, part of SLO gene fragments are cloned, and the part of SLO genes are cloned into an expression vector of escherichia coli and the like so as to realize mass expression and facilitate purification. In particular, the invention provides a DNA sequence which has a base sequence as shown in SEQ ID NO:1. According to the invention, the truncated-form SLO sequence can greatly improve the yield of SLO protein; more than 150 mg of SLO protein can be obtained through purification of one liter of bacterial culture, and the purity is more than 90%; immunological tests prove that the sectionally expressed SLO still maintains the specific immunogenicity.

The invention provides compositions comprising one or more isolated LDH-deficient mutans streptococcus strains and one or more isolated S. oralis strains and / or one or more isolated S. uberis strains. Compositions of the invention are useful to maintain oral health, by for example treating and / or preventing one or more symptoms of dental caries, periodontitis and / or other oral cavity diseases or wounds.

The present disclosure relates to devices and methods for rapidly detecting streptococcus bacteria. An illustrative device includes a first elongate handle connected to a first edible portion and a second elongate handle connected to a second edible portion. The first and second elongate handles are connected by a banding material. The first and second edible portions are inserted into the mouth of an individual for receiving a saliva sample.

Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.

The invention discloses a composition for treating diarrhea and a preparation thereof, relating to a medicinal composition for stopping the diarrhea. The invention also relates to a preparation of the medicinal composition for stopping the diarrhea. The medicinal composition is mainly prepared from the main raw materials of 1 part of Racecadotril and 0.25-25 parts of berberine hydrochloride as well as 0.01-250 parts of auxiliary materials in proportion. The medicinal composition has scientific and reasonable prescription, and can be used for inhibiting the rise of calcium ion concentration in colon smooth muscle cells and improving the motion functional coordination of the intestinal tract to realize the effect on stopping the diarrhea mainly by inhibiting the activity of enkephalinase and further inhibiting the excessive secretion of water and electrolyte via the Racecadotril, and simultaneously by the stronger bactericidal effect of the berberine hydrochloride on escherichia coli, Streptococcus hemolyticus, Diplococcus pneumoniae and the like.

The present invention provides for recombinant Endo-D and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor by transglycosylation. Such recombinant Endo-D and selected mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain.

Group A streptococcal (GAS) antigens useful for providing immunity against pyogenes infection.

The invention discloses primers, probes and a kit for rapidly detecting mycoplasma bovis on site. The kit comprises a forward primer sequence shown as SEQ No.1, a reverse primer sequence shown as SEQ No.2, and a probe sequence shown as SEQ No.3, wherein the 5'-terminal of the reverse primer sequence is labeled by biotin; the 5'-terminal of the probe sequence is labeled by FAM, dSpacer is arranged at the position away from the 5'-terminal by 30 basic groups, and the 3'-terminal is blocked by C3-spacer. The primers, the probe assembly and the kit for detecting the mycoplasma bovis RPA-nfo are high in sensitivity and strong in specificity, the mycoplasma bovis DNA of 10 copies / reaction can be detected at the minimum, and the primers and the probes for detecting RPA-nfo respectively have no cross reaction with other mycoplasmas, as well as the bacteria including pasteurella multocida, mannheimia haemolytica, arcanobacterium pyogenes, histophilus somni, and streptococcus pneumoniae.

Macrolide resistance associated with macrolide efflux (mef) in Streptococcus pneumoniae has been defined with respect to the genetic structure and dissemination of a novel mefE-containing chromosomal insertion element. The mefE gene is found on the 5′-end of a 5.5 kb or 5.4 kb insertion designated mega (macrolide efflux genetic assembly) found in at least four distinct sites of the pneumococcal genome. The element is transformable and confers macrolide resistance to susceptible S. pneumoniae. The first two open reading frames (ORFs) of the element form an operon composed of mefE and a predicted ATP-binding cassette homologous to msrA. Convergent to this efflux operon are three ORFs with homology to stress response genes of Tn5252. Mega is related to mefA-containing element Tn1207.1. Macrolide resistance due to mega has been rapidly increased by clonal expansion of bacteria containing it and horizontally by transformation of previously sensitive bacteria.

The invention provides a method for producing a deodorant microbial agent. The method comprises the following steps: carrying out high-density fermentation on streptococcus thermophilus, pseudomonas putida, rhodopseudomonas palustris, bacillus pumilus and enterococcus faecium, and then freezing and drying; adding a sodium citrate solution of which the concentration is 8-10% according to 1-5% of mass-volume ratio after mixing according to the ratio, so as to prepare a liquid deodorant product. The concentration of bad smells such as an ammonia gas, hydrogen sulfide and the like in the air in the places such as a toilet, a farm and a wasteyard can be effectively reduced; an odor-generating element is also restrained, so that the air quality and surroundings of people are significantly improved. The production method disclosed by the invention is simple, and adapts to most of existing fermentation technologies and equipments; large-scale popularization and application are facilitated.

An use of the high-purity product or raw liquid of lysozyme and associated derivative in preventing and treating the diseases caused by vibrio, streptococcus, Edward bacterium, etc of the fish, crab,and shrimp cultured in seawater or fresh water is disclosed.